2009 News

• 11.10.2009
  Press Release IR News

  Santen Announces Financial Result for the Second Quarter ended September 30, 2009

• 11.10.2009
  Press Release IR News

  Revision of Financial Forecast

• 08.04.2009
  Press Release IR News

  Santen Announces Financial Result for the First Quarter ended June 30, 2009

• 07.03.2009
  Press Release IR News

  Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)

• 06.24.2009
  Press Release IR News

  Notice on the Allotment of Stock Options (Stock Acquisition Rights)

• 05.12.2009
  Press Release IR News

  Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options

• 05.12.2009
  Press Release IR News

  Notice on Board of Directors

• 05.12.2009
  Press Release IR News

  Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options

• 05.12.2009
  Press Release IR News

  Santen Announces Financial Results for the Year ended March 31, 2009

• 04.15.2009
  Press Release IR News

  Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost, Treatment for Glaucoma and Ocular Hypertension

• 03.03.2009
  Press Release

  Santen to Launch Sante FX V Plus OTC Eye Drop

• 03.03.2009
  Press Release IR News

  Santen Pharmaceutical Co., Ltd. (Santen) licenses development, manufacturing and marketing rights of its hydrophobic acrylic lens material to Bausch & Lomb Inc.(B&L)

• 02.05.2009
  Press Release IR News

  Santen Announces Financial Result for the Third Quarter ended December 31, 2008

News Archive